Validation of a multimarker model for assessing risk of type 2 diabetes from a five-year prospective study of 6784 Danish people (Inter99)

Journal of Diabetes Science and Technology

Volumn 3, Issue 4, 2009, Pages 748-755

  Urdea, Mickey ^a   Kolberg, Janice ^a   Wilber, Judith ^a   Gerwien, Robert ^a   Moler, Edward ^a   Rowe, Michael ^a   Jorgensen, Paul ^a   Hansen, Torben ^b   Pedersen, Oluf ^b   Jørgensen, Torben ^c   Borch Johnsen, Knut ^b  

^a Tethys Bioscience   (United States)

^b STENO DIABETES CENTER   (Denmark)

^c GLOSTRUP UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Adiponectin; Biomarkers; C reactive protein; Diabetes risk score; Ferritin; Hemoglobin A1c; Impaired fasting glucose; Insulin; Interleukin 2 receptor alpha; Metabolic syndrome; PreDx diabetes risk score; Stratified risk assessment; Type 2 diabetes

Indexed keywords

BIOLOGICAL MARKER;

ARTICLE; BIOLOGICAL MODEL; BLOOD; DENMARK; DISEASE COURSE; GLUCOSE BLOOD LEVEL; HUMAN; NON INSULIN DEPENDENT DIABETES MELLITUS; PROSPECTIVE STUDY; RISK; RISK ASSESSMENT; VALIDATION STUDY;

BIOLOGICAL MARKERS; BLOOD GLUCOSE; DENMARK; DIABETES MELLITUS, TYPE 2; DISEASE PROGRESSION; HUMANS; MODELS, BIOLOGICAL; PROSPECTIVE STUDIES; RISK; RISK ASSESSMENT;

EID: 75149178604     PISSN: None     EISSN: 19322968     Source Type: Journal    
DOI: 10.1177/193229680900300422     Document Type: Conference Paper

References (20)

1. Unwin N, Shaw J, Zimmet P, Alberti KG. Impaired glucose tolerance and impaired fasting glycaemia: the current status on definition and intervention. Diabet Med. 2002;19(9):708-23. (Pubitemid 35013848)
2. Stern MP, Williams K, Haffner SM. Identification of persons at high risk for type 2 diabetes mellitus: do we need the oral glucose tolerance test? Ann Intern Med. 2002;136(8):575-81. (Pubitemid 34407041)
3. Wong TY, Liew G, Tapp RJ, Schmidt MI, Wang JJ, Mitchell P, Klein R, Klein BE, Zimmet P, Shaw J. Relation between fasting glucose and retinopathy for diagnosis of diabetes: three population-based cross-sectional studies. Lancet. 2008;371(9614):736-43. (Pubitemid 351288874)
4. Abdul-Ghani MA, Williams K, DeFronzo RA, Stern M. What is the best predictor of future type 2 diabetes? Diabetes Care. 2007;30(6):1544-8. (Pubitemid 46871168)
5. Wilson PW, Meigs JB, Sullivan L, Fox CS, Nathan DM, D'Agostino RB Sr. Prediction of incident diabetes mellitus in middle-aged adults: the Framingham Offspring Study. Arch Intern Med. 2007;167(10):1068-74. (Pubitemid 46835795)
6. Mohamed Q, Evans A. Retinopathy, plasma glucose, and the diagnosis of diabetes. Lancet. 2008;371(9614):700-2. (Pubitemid 351288857)
7. Ramachandran S, Labib MH. Hyperlipidaemia and primary prevention of coronary heart disease: are the right patients being treated? J Cardiovasc Risk. 2000;7(4):245-9.
8. Backlund L, Bring J, Strender L-E. How accurately do general practitioners and students estimate coronary risk in hypercholesterolaemic patients? Primary Health Care Res Dev. 2004;5:145-52.
9. Eaton CB, Galliher JM, McBride PE, Bonham AJ, Kappus JA, Hickner J. Family physician's knowledge, beliefs, and self-reported practice patterns regarding hyperlipidemia: a National Research Network (NRN) survey. J Am Board Fam Med. 2006;19(1):46-53. (Pubitemid 44046993)
10. Rhodes CJ. Type 2 diabetes-a matter of beta-cell life and death? Science. 2005;307(5708):380-4. (Pubitemid 40139973)
11. Petersen KF, Shulman GI. Etiology of insulin resistance. Am J Med. 2006;119(5 Suppl 1):S10-6.
12. Martin BC, Warram JH, Krolewski AS, Bergman RN, Soeldner JS, Kahn CR. Role of glucose and insulin resistance in development of type 2 diabetes mellitus: results of a 25-year follow-up study. Lancet. 1992;340(8825):925-9.
13. Goldfine AB, Bouche C, Parker RA, Kim C, Kerivan A, Soeldner JS, Martin BC, Warram JH, Kahn CR. Insulin resistance is a poor predictor of type 2 diabetes in individuals with no family history of disease. Proc Natl Acad Sci U S A. 2003;100(5):2724-9. (Pubitemid 36297566)
14. Kolberg JA, Jørgensen T, Gerwien RW, Hamren S, McKenna MP, Moler E, Rowe MW, Urdea MS, Xu XM, Hansen T, Pedersen O, Borch-Johnsen K. Development of a type 2 diabetes risk model from a panel of serum biomarkers from the Inter99 cohort. Diabetes Care. 2009;32(7):1207-12.
15. Jørgensen T, Borch-Johnsen K, Thomsen TF, Ibsen H, Glümer C, Pisinger C. A randomized non-pharmacological intervention study for prevention of ischaemic heart disease: baseline results Inter99. Eur J Cardiovasc Prev Rehabil. 2003;10(5):377-86.
16. Goldfine AB, Gerwien R, Kolberg J, O'Shea S, Eastman PS, Fernandez E, Hamilton T, Hein G, McKenna MP, Xu X, Patti ME. Multivariate models of biomarkers in fasting serum to estimate glucose tolerance, insulin sensitivity, and insulin secretion. [In peer review 2009.]
17. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28(7):412-9. (Pubitemid 15018832)
18. Diabetes Trials Unit. HOMA calculator. Oxford: University of Oxford; 2007. http://www.dtu.ox.ac.uk/homa.
19. American Diabetes Association. Standards of medical care in diabetes - 2009. Diabetes Care. 2009;33 Suppl 1:S13-61.
20. National Heart Lung and Blood Institute Diseases and Conditions Index. How is metabolic syndrome diagnosed? http://www.nhlbi.nih.gov/health/dci/ Diseases/ms/ms-diagnosis.html.